Survival differences in pediatric pulmonary arterial hypertension: Clues to a better understanding of outcome and optimal treatment strategies

Journal of the American College of Cardiology

Volumn 63, Issue 20, 2014, Pages 2159-2169

  Zijlstra, Willemijn M H ^a   Douwes, Johannes M ^a   Rosenzweig, Erika B ^b   Schokker, Sandor ^a   Krishnan, Usha ^b   Roofthooft, Marcus T R ^a   Miller Reed, Kathleen ^c   Hillege, Hans L ^d   Ivy, D Dunbar ^c   Berger, Rolf M F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Columbia University College of Physicians and Surge ^*  (United States)

^c CHILDREN S HOSPITAL COLORADO   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

pediatrics; pulmonary hypertension; survival

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT;

ARTERIAL PRESSURE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN PULMONARY TO SYSTEMIC ARTERIAL PRESSURE RATIO; MONOTHERAPY; ONSET AGE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VASCULAR RESISTANCE INDEX; RESPIRATORY TRACT PARAMETERS; SENSITIVITY ANALYSIS; SURVIVAL RATE; COHORT ANALYSIS; HEMODYNAMIC PARAMETERS; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; RETROSPECTIVE STUDY;

PEDIATRICS; PULMONARY HYPERTENSION; SURVIVAL;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VASCULAR RESISTANCE;

EID: 84901044370     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.02.575     Document Type: Article

References (27)

1. G.E. D'Alonzo, R.J. Barst, and S.M. Ayres et al. Survival in patients with primary pulmonary hypertension. results from a national prospective registry Ann Intern Med 115 1991 343 349
2. R.M. Berger, M. Beghetti, and T. Humpl et al. Clinical features of paediatric pulmonary hypertension: a registry study Lancet 379 2012 537 546
3. A. Fraisse, X. Jais, and J.M. Schleich et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France Arch Cardiovasc Dis 103 2010 66 74
4. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
5. V.V. McLaughlin, O. Sitbon, and D.B. Badesch et al. Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2005 244 249
6. S.G. Haworth, and A.A. Hislop Treatment and survival in children with pulmonary arterial hypertension: the UK pulmonary hypertension service for children 2001-2006 Heart 95 2009 312 317
7. D.D. Ivy, E.B. Rosenzweig, J.C. Lemarie, M. Brand, D. Rosenberg, and R.J. Barst Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings Am J Cardiol 106 2010 1332 1338
8. E.B. Rosenzweig, D.D. Ivy, and A. Widlitz et al. Effects of long-term bosentan in children with pulmonary arterial hypertension J Am Coll Cardiol 46 2005 697 704
9. R.L. van Loon, M.T. Roofthooft, and T. Delhaas et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies Am J Cardiol 106 2010 117 124
10. R.J. Barst, M.D. McGoon, C.G. Elliott, A.J. Foreman, D.P. Miller, and D.D. Ivy Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management Circulation 125 2012 113 122
11. G. Simonneau, I.M. Robbins, and M. Beghetti et al. Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 2009 S43 S54
12. N. Galie, M.M. Hoeper, and M. Humbert et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
13. WHO Multicentre Growth Reference Study Group WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development 2006 World Health Organization Geneva (312 pages)
14. M. de Onis, A.W. Onyango, E. Borghi, A. Siyam, C. Nishida, and J. Siekmann Development of a WHO growth reference for school-aged children and adolescents Bull World Health Organ 85 2007 660 667
15. R.J. Barst, G. Maislin, and A.P. Fishman Vasodilator therapy for primary pulmonary hypertension in children Circulation 99 1999 1197 1208
16. O. Sitbon, M. Humbert, and X. Jais et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 2005 3105 3111
17. J.L. Orford, R. Lennon, and S. Melby et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry J Am Coll Cardiol 40 2002 1567 1572
18. R.L. van Loon, M.T. Roofthooft, and H.L. Hillege et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005 Circulation 124 2011 1755 1764
19. O. Sitbon, M. Humbert, and H. Nunes et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
20. S. Moledina, A.A. Hislop, H. Foster, I. Schulze-Neick, and S.G. Haworth Childhood idiopathic pulmonary arterial hypertension: a national cohort study Heart 96 2010 1401 1406
21. A.E. Lammers, I. Adatia, and M.J. Cerro et al. Functional classification of pulmonary hypertension in children: report from the PVRI pediatric taskforce, Panama 2011 Pulm Circ 1 2011 280 285
22. J.M. Douwes, R.L. van Loon, and E.S. Hoendermis et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria Eur Heart J 32 2011 3137 3146
23. M.E. Van Albada, F.G. Loot, R. Fokkema, M.T. Roofthooft, and R.M. Berger Biological serum markers in the management of pediatric pulmonary arterial hypertension Pediatr Res 63 2008 321 327
24. S. Takatsuki, B.D. Wagner, and D.D. Ivy B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension Congenit Heart Dis 7 2012 259 267
25. S. Rich, E. Kaufmann, and P.S. Levy The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N Engl J Med 327 1992 76 81
26. M.M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, and J. Niedermeyer Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Eur Respir J 26 2005 858 863
27. O. Sitbon, and N. Galie Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals Eur Respir Rev 19 2010 272 278